Teva Concedes On US Gimoti ANDA, Voiding 180-Day Exclusivity
Change Of ANDA Certification Could Mean Years Added To Brand Monopoly
Teva will not engage in paragraph IV patent-infringement litigation with Evoke Pharma over the originator’s Gimoti (metoclopramide) nasal spray treatment for diabetic gastroparesis, following a court order.
